Atlas Trials

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Clinical trial NCT01704963 · COMPLETED

Trial details

NCT number
NCT01704963
Sponsor
Janssen Pharmaceutical K.K.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Mature B-cell Neoplasms
Start date
2012-09-12
Primary completion
2015-11-20
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.